Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in Secondary Angiosarcomas
NCT04873375Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2022
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in angiosarcoma, sponsored by Radboud University Medical Center. Started Jan 2022; status: completed.
02
Drugs
cemiplimab
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on NCT04873375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04873375.